Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Astellas acquires Nanna Therapeutics

by Lisa M. Jarvis
April 24, 2020 | A version of this story appeared in Volume 98, Issue 16

Astellas Pharma paid roughly $15 million to acquire UK-based Nanna Therapeutics, which is developing therapies that modulate function of the cell’s power source, mitochondria. Nanna’s DNA-encoded library (DEL) and screening platform allow it to conduct phenotypic screens that it says were not possible with older generations of DELs. Astellas says the addition will accelerate its research into autophagy, mitophagy, aging, and immunometabolism.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.